| |
Latest 10 SEC filings (by transaction date) for MDGL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -721 | $216.98 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -375 | $216.08 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -1,804 | $214.68 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -2,190 | $213.85 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -1,363 | $212.85 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -5,009 | $211.84 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -8,827 | $210.99 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 12,489 | $105.08 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Stock Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -12,489 | |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Stock Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -10,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for MDGL within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -721 | $216.98 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -375 | $216.08 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -1,804 | $214.68 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -2,190 | $213.85 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -1,363 | $212.85 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -5,009 | $211.84 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | S - Open market or private sale | -8,827 | $210.99 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 12,489 | $105.08 |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Stock Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -12,489 | |
May 16/24 | May 14/24 | Craves Fred B | Direct Ownership | Stock Option (right to buy) | M - Exercise or conversion exempt under rule 16b-3 | -10,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Regeneron Pharmaceuticals (OQ:REGN) |
Neurocrine Biosciences (OQ:NBIX) |
Vertex Pharmaceuticals (OQ:VRTX) |